{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"135"}]}],"title":"p-ERK: Participant 1, pre-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"109"}]}],"title":"p-ERK: Participant 1, post-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"193"}]}],"title":"p-ERK: Participant 2, pre-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"138"}]}],"title":"p-ERK: Participant 2, post-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"148"}]}],"title":"p-ERK: Participant 3, pre-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"65"}]}],"title":"p-ERK: Participant 3, post-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"80"}]}],"title":"p-ERK: Participant 4, pre-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"p-ERK: Participant 4, post-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"130"}]}],"title":"p-ERK: Participant 5, pre-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"99"}]}],"title":"p-ERK: Participant 5, post-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"68"}]}],"title":"p-ERK: Participant 6, pre-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"p-ERK: Participant 6, post-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"128"}]}],"title":"p-ERK: Participant 7, pre-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"81"}]}],"title":"p-ERK: Participant 7, post-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"196"}]}],"title":"p-ERK: Participant 8, pre-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"75"}]}],"title":"p-ERK: Participant 8, post-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"164"}]}],"title":"p-ERK: Participant 9, pre-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"109"}]}],"title":"p-ERK: Participant 9, post-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"239"}]}],"title":"p-ERK: Participant 10, pre-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"78"}]}],"title":"p-ERK: Participant 10, post-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"130"}]}],"title":"p-AKT: Participant 1, pre-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"180"}]}],"title":"p-AKT, Participant 1, post-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"76"}]}],"title":"p-AKT: Participant 2, pre-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50"}]}],"title":"p-AKT, Participant 2, post-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"192"}]}],"title":"p-AKT: Participant 3, pre-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"277"}]}],"title":"p-AKT, Participant 3, post-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}],"title":"p-AKT: Participant 4, pre-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"135"}]}],"title":"p-AKT, Participant 4, post-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"55"}]}],"title":"p-AKT: Participant 5, pre-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"p-AKT, Participant 5, post-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"145"}]}],"title":"p-AKT: Participant 6, pre-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"p-AKT, Participant 6, post-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}]}],"title":"p-AKT: Participant 7, pre-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"p-AKT, Participant 7, post-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"183"}]}],"title":"p-AKT: Participant 8, pre-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"123"}]}],"title":"p-AKT, Participant 8, post-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"278"}]}],"title":"p-AKT: Participant 9, pre-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"289"}]}],"title":"p-AKT, Participant 9, post-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"73"}]}],"title":"p-AKT: Participant 10, pre-dose score"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"p-AKT, Participant 10, post-dose score"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"p-ERK and p-AKT, biomarkers in tumor biopsies, were assessed for participants with BRAF mutant colorectal cancer. The H-score, which is a composite score that comprises intensity and percentage of staining, is a method of assessing the amount of protein or phospho-protein present in a biopsy sample. The score is obtained by the formula: (3 \\* percentage of strongly staining nuclei) + (2 \\* percentage of moderately staining nuclei) + (percentage of weakly staining nuclei). The H-score ranges from 0 to 300, with a score of 0 representing the absence of any of the target protein and an H-score of 300 representing maximum staining and intensity of the target protein.","groups":[{"description":"Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib (75 mg or 150 mg) gelatin capsules BID and trametinib (1 mg, 1.5 mg, or 2 mg) tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.","id":"OG000","title":"Part B: Dabrafenib + Trametinib"}],"paramType":"NUMBER","populationDescription":"Biomarker Population: participants with H-score data for pre- and post-biopsy pairs","reportingStatus":"POSTED","timeFrame":"Screening and at disease progression (up to approximately 8 years)","title":"Part B: Pre- and Post-dose H-scores for Individual Participants","type":"SECONDARY","unitOfMeasure":"scores on a scale"}